# A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications

> **NCT06004947** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 32 (actual)

## Conditions studied

- Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

## Interventions

- **DRUG:** CCX168
- **DRUG:** Midazolam
- **DRUG:** Celecoxib
- **DRUG:** Itraconazole
- **DRUG:** Rifampicin

## Key facts

- **NCT ID:** NCT06004947
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-14
- **Primary completion:** 2016-03-15
- **Final completion:** 2016-06-10
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2023-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06004947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06004947, "A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06004947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*